Zymeworks Inc.
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
ZYME$31.46+2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Equity
Condensed Consolidated Statement of Changes in Stockholders’ Equity
(Expressed in thousands of U.S. dollars except share data)
| Preferred stock · Exchangeable shares · Common stock · Accumulateddeficit · Accumulatedothercomprehensive loss · Additionalpaid-incapital · Totalstockholders’equity | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount · Shares · Amount | ||||||||||
| Balance at January 1, 2025 | 1 | $— | 570,637 | $8,188 | 68,964,319 | $1,015,618 | $(830,335) | $(6,952) | $152,249 | $338,768 |
| Issuance of common stock on exercise of options | — | — | — | — | 84,863 | 1,208 | — | — | (437) | 771 |
| Issuance of common stock through employee stock purchase plan | — | — | — | — | 74,274 | 724 | — | — | — | 724 |
| Issuance of common stock upon vesting of restricted stock units (“RSUs”) | — | — | — | — | 460,620 | 4,390 | — | — | (4,390) | — |
| Issuance of common stock for retracted exchangeable shares (note 8a) | — | — | (735) | (10) | 735 | 10 | — | — | — | — |
| Stock-based compensation | — | — | — | — | — | — | — | — | 6,794 | 6,794 |
| Net loss | — | — | — | — | — | — | (22,636) | — | — | (22,636) |
| Other comprehensive income | — | — | — | — | — | — | — | 546 | — | 546 |
| Balance at March 31, 2025 | 1 | $— | 569,902 | $8,178 | 69,584,811 | $1,021,950 | $(852,971) | $(6,406) | $154,216 | $324,967 |
| Preferred stock · Exchangeable shares · Common stock · Accumulateddeficit · Accumulatedothercomprehensiveloss · Additionalpaid-incapital · Totalstockholders’equity | ||||||||||
| Shares · Amount · Shares · Amount · Shares · Amount | ||||||||||
| Balance at January 1, 2024 | 1 | $— | 651,219 | $9,345 | 70,115,997 | $997,227 | $(677,437) | $(6,603) | $142,274 | $464,806 |
| Issuance of common stock on exercise of options | — | — | — | — | 203,518 | 2,581 | — | — | (626) | 1,955 |
| Issuance of common stock through employee stock purchase plan | — | — | — | — | 52,905 | 577 | — | — | — | 577 |
| Issuance of common stock upon vesting of RSUs | — | — | — | — | 224,104 | 1,939 | — | — | (1,939) | — |
| Issuance of common stock for retracted exchangeable shares (note 8a) | — | — | (80,582) | (1,157) | 80,582 | 1,157 | — | — | — | — |
| Stock-based compensation | — | — | — | — | — | — | — | — | 3,435 | 3,435 |
| Net loss | — | — | — | — | — | — | (31,653) | — | — | (31,653) |
| Other comprehensive loss | — | — | — | — | — | — | — | (1,121) | — | (1,121) |
| Balance at March 31, 2024 | 1 | $— | 570,637 | $8,188 | 70,677,106 | $1,003,481 | $(709,090) | $(7,724) | $143,144 | $437,999 |
The accompanying notes are an integral part of these financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.